Gastric Cancer Industry Analysis and Forecast to 2034 - Insights on the Global Market's Rapid Growth to $18.43 Billion, Emerging Therapies, and Regional Trends
20. November 2024 07:55 ET
|
Research and Markets
Dublin, Nov. 20, 2024 (GLOBE NEWSWIRE) -- The "Gastric Cancer Market by Type, by Diagnosis, by Treatment, by Route of Administration, by End-users, and by Region" report has been added to ...
Global Immune Checkpoint Inhibitors Market Analysis Report 2024-2030: Growing FDA Approvals of Immune Checkpoint Inhibitors and Increasing Funding for Advancing Cancer Immunotherapy
24. Juni 2024 10:26 ET
|
Research and Markets
Dublin, June 24, 2024 (GLOBE NEWSWIRE) -- The "Global Immune Checkpoint Inhibitors Market Size, Share & Trends Analysis Report by Type (PD-1, PD-L1, CTLA-4), Application (Lung Cancer, Breast...
Immune Checkpoint Drugs in Oncology: Analytical Tool – A Must-Have Handbook for Business Developers, BI/CI Operatives, and Clinical Developers
25. April 2024 10:26 ET
|
Research and Markets
Dublin, April 25, 2024 (GLOBE NEWSWIRE) -- The "Immune-checkpoint Drugs in Oncology: Analytical Tool" report has been added to ResearchAndMarkets.com's offering.Cancer cells sometimes find ways to...
Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
16. Januar 2024 17:01 ET
|
Adagene Inc.
- Data from first tranche of MSS CRC patients treated with ADG126 10 mg/kg every three weeks (Q3W) in dose expansion showed clinical benefit including confirmed responses at higher, more frequent and...
Lerapolturev (Formerly Known as PVSRIPO) + Pembrolizumab for Glioblastoma Multiforme (GBM): Emerging Drug Insights and Market Forecast Report, 2019-2023 & 2023-2032
22. November 2023 08:58 ET
|
Research and Markets
Dublin, Nov. 22, 2023 (GLOBE NEWSWIRE) -- The "Lerapolturev + Pembrolizumab Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.This report...
Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Advanced Cutaneous Melanoma
15. November 2023 09:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today provided updated data from an ongoing Phase 1b/2 clinical trial of investigational cancer immunotherapy PV-10 (rose...
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
22. Oktober 2023 06:01 ET
|
HOOKIPA Pharma Inc.
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line setting—doubling historical ORR reported with...
Metastatic Cancer Drug Market Thrives with Collaborative Innovations: Pfizer, Sanofi, and Merck Leading the Charge
15. September 2023 10:18 ET
|
Research and Markets
Dublin, Sept. 15, 2023 (GLOBE NEWSWIRE) -- The "Global Metastatic Cancer Drugs Market Size, Share & Industry Trends Analysis Report By Distribution Channel, By Indication, By Therapy (Targeted...
7 Hills Pharma Surpasses $25MM Milestone in Nondilutive Funding
22. Mai 2023 13:05 ET
|
7 Hills Pharma
HOUSTON, May 22, 2023 (GLOBE NEWSWIRE) -- 7 Hills Pharma LLC (“7 Hills” or “7HP”) announced today that it has been awarded $13.5MM in nondilutive grant funds from the Cancer Prevention &...
Global Checkpoint Inhibitors Market Report 2023: Rising Number of Cancer Cases Drives Growth
24. April 2023 13:18 ET
|
Research and Markets
Dublin, April 24, 2023 (GLOBE NEWSWIRE) -- The "Checkpoint Inhibitors Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. This report provides strategists,...